Calculation of Phase 2 dose-finding study sample size for reliable Phase 3 dose selection

被引:0
作者
Liu, Fang [1 ,2 ]
Zhao, Qing [1 ]
Rodgers, Anthony J. [1 ]
Mehrotra, Devan V. [1 ]
机构
[1] Merck & Co Inc, Biostat & Res Decis Sci, Rahway, NJ USA
[2] Merck & Co Inc, Biostat & Res Decis Sci, Rahway, NJ 07065 USA
关键词
dose-finding study; MCP-Mod; Phase 3 dose selection; sample size determination; COMBINING MULTIPLE COMPARISONS; MODEL SELECTION; OPTIMAL DESIGNS;
D O I
10.1002/pst.2330
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Sample sizes of Phase 2 dose-finding studies, usually determined based on a power requirement to detect a significant dose-response relationship, will generally not provide adequate precision for Phase 3 target dose selection. We propose to calculate the sample size of a dose-finding study based on the probability of successfully identifying the target dose within an acceptable range (e.g., 80%-120% of the target) using the multiple comparison and modeling procedure (MCP-Mod). With the proposed approach, different design options for the Phase 2 dose-finding study can also be compared. Due to inherent uncertainty around an assumed true dose-response relationship, sensitivity analyses to assess the robustness of the sample size calculations to deviations from modeling assumptions are recommended. Planning for a hypothetical Phase 2 dose-finding study is used to illustrate the main points. Codes for the proposed approach is available at .
引用
收藏
页码:1076 / 1088
页数:13
相关论文
共 17 条
[1]  
[Anonymous], 2014, Qualification opinion of MCPMod as an efficient statistical methodology for modelbased design and analysis of phaseII dose finding studies under model uncertainty
[2]  
Bornkamp B., 2023, MCP MOD FAQ
[3]   Innovative approaches for designing and analyzing adaptive dose-ranging trials [J].
Bornkamp, Bjoern ;
Bretz, Frank ;
Dmitrienko, Alex ;
Enas, Greg ;
Gaydos, Brenda ;
Hsu, Chyi-Hung ;
Koenig, Franz ;
Krams, Michael ;
Liu, Qing ;
Neuenschwander, Beat ;
Parke, Tom ;
Pinheiro, Jose ;
Roy, Amit ;
Sax, Rick ;
Shen, Frank .
JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2007, 17 (06) :965-995
[4]   Combining multiple comparisons and modeling techniques in dose-response studies [J].
Bretz, F ;
Pinheiro, JC ;
Branson, M .
BIOMETRICS, 2005, 61 (03) :738-748
[5]   Practical considerations for optimal designs in clinical dose finding studies [J].
Bretz, Frank ;
Dette, Holger ;
Pinheiro, Jose C. .
STATISTICS IN MEDICINE, 2010, 29 (7-8) :731-742
[6]   Model selection: An integral part of inference [J].
Buckland, ST ;
Burnham, KP ;
Augustin, NH .
BIOMETRICS, 1997, 53 (02) :603-618
[7]   Statistical considerations on implementing the MCP-Mod method for binary endpoints in clinical trials [J].
Chen, Jingjing ;
Liu, Tina .
CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2020, 19
[8]   Power and sample size for dose-finding studies with survival endpoints under model uncertainty [J].
Deng, Qiqi ;
Bai, Xiaofei ;
Liu, Dacheng ;
Roy, Dooti ;
Ying, Zhiliang ;
Lin, Dan-Yu .
BIOMETRICS, 2019, 75 (01) :308-314
[9]   Optimal Designs for Dose-Finding Studies [J].
Dette, Holger ;
Bretz, Frank ;
Pepelyshev, Andrey ;
Pinheiro, Jose .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 2008, 103 (483) :1225-1237
[10]  
Pinheiro J, 2017, HDB METHODS DESIGNIN, P229